Vision-Sciences, Inc. Appoints Warren Bielke Interim Chief Executive Officer

Obtains $5 Million in Financing

Will Announce Second Quarter and First Half Results
ORANGEBURG, N.Y., Nov. 9, 2009 (GLOBE NEWSWIRE) -- Vision-Sciences, Inc.,
(Nasdaq:VSCI) ("Vision-Sciences" or the "Company") announced today the
appointment of Mr. Warren Bielke, a director, as Interim Chief Executive
Officer. Mr. Bielke replaces Mr. Ron Hadani who resigned as President, Chief
Executive Officer and as a member of the Board of Directors of Vision-Sciences,
effective immediately. Mr. Hadani resigned for personal reasons. The Board
expressed gratitude to Mr. Hadani for his service to Vision-Sciences.

Mr. Bielke, a Vision-Sciences' director since 2005, has been actively engaged in
managing the Company's sales and marketing efforts as a consultant since April
2009. "We are very pleased that Warren Bielke has agreed to serve as Interim
CEO," said Mr. Lewis Pell, Chairman of the Board. "Warren's deep knowledge of
Vision-Sciences and extensive experience in sales and marketing of advanced
medical products will provide the leadership necessary to accelerate
commercialization of our industry-leading technology during this transition
period." Mr. Bielke previously served as the President of Pentax Precision
Instruments Corp., a leading manufacturer of endoscopy equipment.

A special committee of the Board, composed of independent directors, has
initiated the search for a new chief executive officer.

"The appointment of Mr. Bielke reflects the Board's determination to assist the
Company in fully realizing its commercial potential," Mr. Pell added. I want to
assure the shareholders of Vision-Sciences that the Company is committed to
achieving its financial goals."

New Financing

Vision-Sciences also announced that it has entered into a Revolving Loan
Agreement with Mr. Pell in which he has agreed to provide a revolving loan of up
to $5.0 million dollars to the Company for working capital purposes. Amounts
advanced under the Revolving Loan will bear interest at a rate of 7.5% per year.
In connection with this agreement, the Company will issue to Mr. Pell a fully
vested warrant to purchase up to 272,727 shares of Vision-Sciences' Common Stock
(representing 7.5% warrant coverage), at an exercise price of $1.375 per share,
and a second warrant to purchase up to an additional 378,788 shares of
Vision-Sciences Common Stock (representing up to an additional 12.5% warrant
coverage) at an exercise price of $1.65 per share. The number of shares into
which the second warrant will vest is based on the percentage of the revolving
loan that has been advanced.

Second Quarter and First Half Results Call Planned

Vision-Sciences will issue results for its second quarter and first half of
fiscal 2010 ended September 30, 2009 on November 12, 2009 after the market
closes. Vision-Sciences will host a conference call on November 13, 2009 at 8:30
am EST, during which Lewis Pell, Chairman, Warren Bielke, Interim Chief
Executive Officer, and Katherine Wolf, Chief Financial Officer, will provide an
update on the Company and discuss second quarter and first half results. The
toll-free dial-in number for the call is 888.500.6973. Please dial in five
minutes prior to the call to register. A recording of the call will be available
through November 20, 2009. The toll free replay dial-in is 888.203.1112. The
replay pass code is 3034974. The call may also be accessed via a live audio
webcast available in the investor relations section of Vision-Sciences website
at www.visionsciences.com. The audio webcast of the call will be archived and
available for replay through the website.

About Vision-Sciences:

Vision-Sciences develops, manufactures and markets unique flexible endoscopic
products for the urology, gastroenterology, pulmonology and ENT markets,
utilizing its proprietary sterile disposable EndoSheath technology. The
EndoSheath technology provides quick and efficient equipment turnover, and
ensures the patient a contaminant-free endoscope insertion.

The Vision-Sciences, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3876

This release includes forward-looking statements intended to qualify for the
safe harbor from liability established by the Private Securities Litigation
Reform Act of 1995. These forward-looking statements generally can be identified
by phrases such as Vision-Sciences or its management "believes," "expects,"
"allows," "anticipates," or other words or phrases of similar import. Similarly,
statements in this release that describe our business strategy, outlook,
objectives, plans, intentions or goals also are forward-looking statements. All
such forward-looking statements are subject to certain risks and uncertainties
that could cause actual results to differ materially from those in
forward-looking statements. Other risk factors are detailed in our most recent
annual report and other filings with the SEC.

Vision Sciences(R), Slide-On(R), EndoSheath(R) and The Vision System (R) are
registered trademarks owned by Vision-Sciences, Inc.

UPON REQUEST: Bios of Mr. Pell and Mr. Bielke are available

-0-
CONTACT: Vision-Sciences, Inc.
Katherine Wolf, Chief Financial Officer
845-365-0600